Erik Faber MD PhD (@fabermdphd) header
Erik Faber MD PhD (@fabermdphd) profile picture

Onc fellow @MSKCancerCenter w/ #PDAC #GIOnc interest | #medchem 💊 PhD | 🐶 dad | @OslerResidency @umnmstp @dartmouth alum | 🏳️‍🌈 he/him | #mdphd

New York, NY
Joined July 2019
Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)Photo by Erik Faber MD PhD (@fabermdphd)
Finally published! Thanks to all the co-authors for their monumental efforts and the reviewers who helped make this story better. Of all the science I've done to date, I'm the most proud of this. #medchem #allosteric 1/2
Congratulations to all co-authors. DOI 10.1038/s41467-023-38732-x
5
3
66
10,418
Erik Faber MD PhD retweeted
In one of the hardest NCI funding cycles in decades, these institutions captured the most research $ This is the map of where funds flowed in 2026 (full FY'26 dataset in 🧵 below..) How much of an institution's scientific identity can you infer from the mechanisms that got funded? ▪️MSK & MD Anderson tied at ~$128M each, but their portfolios look remarkably different ▫️Mount Sinai stands out for its unusually large U-series portfolio ▫️ UCSF & Dana-Farber have substantial center/program funding What are you seeing? - - - - - Source: NIH RePORTER via @Jori_health - - - - -
2
13
1
47
15,406
My biased solution to this challenge - train more #mdphd physicians in #medchem and similar disciplines, which could: 1) better bridge the Valley of Death b/w preclinical and clinical worlds 2) counteract siloed and reductionist translational efforts nature.com/articles/s41591-0…
3
7
593
nature.com/articles/s41586-0… Aside from helping ALK-driven NSCLC turn into a chronic disease, I'm intrigued by many brushed over aspects of this story: 1. Screening for glues via CRBN-directed 4k library - would love to know more and what other targets have been tested... 1/2
2
1
394
2. No direct measureable affinity between lead compound and ALK - many companies would have killed the project then but thankfully they kept pushing! 3. Also initial hit didn't degrade the target in cells - could have also killed the project! #medchem 2/2
1
49
Erik Faber MD PhD retweeted
The best part of #AACRPanc26: the people. 💜  Mentors and mentees. Friends and collaborators. Scientists, clinicians and patient advocates. Different perspectives, one ☝️united front🛡️against #PancreaticCancer. Science brings us together. Friendship and shared purpose keep us moving forward. Grateful for this community. @AACR #PDAC #KRAS #TeamScience 💜 @MSK_DeptOfMed @MSKCancerCenter @CpcrMsk @PanCAN @lustgartenfdn @NatPancFdn @Pankind_Aus @EileenMOReilly @Jonathanwlee23 @BenWestphalen @GIcancerDoc Collin Weekes @OncoDailyGI @oncodaily
6
32
1,434
Phenomenal work using basic chemical principles/ techniques to target Q61X #RAS. Love the 90s science inspiration and work determining MoA of their activator including key base positioning. Maybe next gen includes small bicyclic heterocycles? Could further lock in base position
2
1,235
Erik Faber MD PhD retweeted
The National Science Foundation (NSF) has issued a 10-page memo signaling a retreat from its traditional role of giving grants to individual researchers to pursue their best ideas and to train the next generation of scientists. Instead, the memo makes clear, NSF will devote the bulk of its resources to addressing the research priorities of President Donald Trump and his administration, many of them technology focused. scim.ag/4ipE1kY
78
409
161
1,021
568,401
Good #medchem example of targeting pseudokinases to #allosteric-ally regulate #PPI / #kinase activity. Reassuring is decent kinome selectivity despite targeting the ATP-binding site, and would love to see further development of C160 covalent activators. cell.com/cell-chemical-biolo…
1
8
1,335
We now need more of this forward looking work in #PDAC While the unique importance of anti-CTLA4 over other ICB is intriguing, I doubt we'll see trials with single agent anti-CTLA4 - at least dual ICI may be reasonable to try with select #RAS inhibitors nature.com/articles/s41467-0…
4
5
1,154
Erik Faber MD PhD retweeted
Among patients with previously untreated metastatic #ColorectalCancer, adding high-dose vitamin D3 to standard chemotherapy plus bevacizumab did not improve progression-free survival compared with standard-dose vitamin D3. Objective response and overall survival were also similar between groups. ja.ma/4yfVsZT
1
11
36
10,003
Erik Faber MD PhD retweeted
The association of COVID vax, ICI, and improved survival was too good to be true: “the previously reported vaccination survival advantage is largely explained by selection bias, with patients who had more favorable prognoses more likely to receive the SARS-CoV-2 vaccination…”
Now online: Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-Related Survival doi.org/10.1158/2159-8290.CD…
3
1
5
2,114
Of course this work is intriguing for a very very select patient. But the disparities in Table 1 re: medical Hx make me skeptical that #SDOH weren't at least partially responsible for difference in outcomes. jamanetwork.com/journals/jam…
1
200